Tics associated with Tourette Syndrome(TS)
Conditions
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a.Patient is younger than 18 years of age on day 1. b.Patient weighs at least 44 pounds (20 kg) on day 1. c.Patient is able to swallow IMP whole. d.Patient and caregiver/adult are willing to adhere to IMP regimen and comply with all study procedures. e.Patient is in good general health, as indicated by medical and psychiatric history as well as physical and neurological examination. f.In the investigator’s opinion, the patient and caregiver/adult have the ability to understand the nature of the study and its procedures, and the patient is expected to complete the study as designed. g.Patient and caregiver/adult provide written informed consent according to local regulations (eg, the patient has provided written assent and/or co-consent for patients 14 years of age and older, as appropriate). h.Females who are postmenarchal or =12 years of age may be included only if they have a negative ß-human chorionic gonadotropin test on day 1 or are sterile. i.Females who are postmenarchal or =12 years of age whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for the duration of the study (ie, starting at screening) and for 30 days or 5 drug half lives, whichever is longer after last dose of IMP. Are the trial subjects under 18? yes Number of subjects for this age range: 260 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range 0 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: a.Patient is 18 years of age or older. b.Patient has a neurologic disorder other than TS that could obscure the evaluation of tics. c.The patient’s predominant movement disorder is stereotypy (coordinated movements that repeat continually and identically) associated with autism spectrum disorder. d.Patient has a confirmed diagnosis of bipolar disorder, schizophrenia, or another psychotic disorder. e.Patient has clinically significant depression at screening or day 1. Note: Patients receiving antidepressant therapy may be enrolled if on a stable dose for at least 6 weeks before screening. f.Patient has a history of suicidal intent or related behaviors within 2 years of screening, defined as: -Previous intent to act on suicidal ideation with a specific plan, irrespective of level of ambivalence, at the time of suicidal thought. -Previous suicidal preparatory acts or behavior g.Patient has a history of a previous actual, interrupted, or aborted suicide attempt. h.Patient has a first-degree relative who has completed suicide. i.Patient has clinically significant obsessive-compulsive disorder (OCD) on day 1 that, in the opinion of the investigator, is the primary cause of impairment. j.Patient has received comprehensive behavioral intervention for tics for TS or cognitive behavioral therapy for OCD within 4 weeks of screening. k.Patient has received any of the following concomitant medications for tics within the specified exclusionary windows of screening: -Within 3 months: depot neuroleptics, botulinum toxin, or tetrabenazine -Within 21 days: reserpine -Within 14 days: neuroleptics (oral), typical and atypical antipsychotics (see Appendix A, Table 7), metoclopramide, levodopa, and dopamine agonists Note: Use of benzodiazepines is allowed if the primary use is not for tics, and dosing has been stable for at least 4 weeks before screening. Note: Use of topiramate (up to 200 mg/day) is allowed if the dosing has been stable for at least 4 weeks before screening. Note: Use of guanfacine or clonidine is allowed if the dosing has been stable for at least 4 weeks before screening. l.Patient has received treatment with deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation for reduction of tics within 4 weeks of the screening visit. m.Patient has an unstable or serious medical illness at screening or day 1. n.Patient has a QT interval corrected for heart rate using Frederica’s formula (QTcF) interval value >450 msec (males) or >460 msec (females), or >480 msec (with right bundle branch block) on 12-lead ECG at screening. Patient requires treatment with drugs known to prolong the QT interval o.Patients with a history of torsade de pointes, congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure. p.Patient has evidence of hepatic impairment, as indicated by: -Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 × the upper limit of the normal range (ULN) at screening -Alkaline phosphatase (ALP) or total bilirubin (Tbil) >2 × ULN at screening Note: Patients with Gilbert’s Syndrome are eligible to participate if approved by the medical monitor. Note: Patients with abnormalities in 2 or more of the following clinical laboratory parameters must be approved for enrollment by the medical monitor: AST, ALT, ALP, and Tbil. q.Patient has evidence of clinically significant renal impairment, indicated by a serum creatinine >1.5 × ULN at screenin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of this study is to evaluate the safety and tolerability of long-term therapy with TEV-50717.;Secondary Objective: The secondary objective of this study are: •to evaluate the efficacy of long-term therapy with TEV-50717 in reducing the severity of TS tics •to confirm long-term maintenance of effect by means of a double-blind, placebo-controlled, randomized drug withdrawal period after 28 weeks of open-label treatment ;Primary end point(s): Safety endpoints Part A: •incidence of adverse events •observed values and changes from day 1 in vital signs •observed values and changes from day 1 in the Children’s Depression Inventory, Second Edition (CDI 2; Parent and Self-report versions) •observed values in the Children’s Columbia-Suicide Severity Rating Scale (C-SSRS) •observed values in electrocardiogram (ECG) parameters and shifts from day 1 for clinically significant abnormal findings •observed values and changes from day 1 in clinical laboratory parameters (hematology, serum chemistry, and urinalysis) The following safety endpoints will be assessed in Part B (Blinded, Randomized Drug Withdrawal Period and Titration Post-Drug Withdrawal): •incidence of adverse events ;Timepoint(s) of evaluation of this end point: Part A: Baseline to Week 54 Part B: week 28 to Week 30 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Efficacy Endpoints: Part A (Day 1, Titration, and Maintenance): •change in the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS) from day 1 to each visit in which the scale is administered •change in the Tourette Syndrome-Clinical Global Impression (TS-CGI) score from day 1 to each visit in which the scale is administered •change in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) score from day 1 to each visit in which the scale is administered •change in the Child and Adolescent Gilles de la Tourette Syndrome – Quality of Life (C&A-GTS QOL) activities of daily living (ADL) subscale score from day 1 to each visit in which the scale is administered Part B (Blinded, Randomized Drug Withdrawal Period and Titration Post-Drug Withdrawal): •change in the TTS of the YGTSS from week 28 to week 30 ;Timepoint(s) of evaluation of this end point: Efficacy endpoints Part A: day 1 to each visit in which the scale is administered Part B: week 28 to week 30 | — |
Countries
Australia, Bulgaria, Canada, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Ukraine, United States
Contacts
Public ContactDr Betsy Garofalo
Nuvelution TS Pharma, INC.
Outcome results
None listed